The amyloidogenic V122I transthyretin variant in elderly black Americans

New England Journal of Medicine

Volumn 372, Issue 1, 2015, Pages 21-29

  Cristina Quarta, C ^a,b   Buxbaum, Joel N ^c   Shah, Amil M ^a   Falk, Rodney H ^a   Claggett, Brian ^a   Kitzman, Dalane W ^d   Mosley, Thomas H ^e   Butler, Kenneth R ^f   Boerwinkle, Eric ^g   Solomon, Scott D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e Department of Medicine Geriatrics ^*  (United States)

^f UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PREALBUMIN; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AFRICAN AMERICAN; AGED; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIASTOLE; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEART AMYLOIDOSIS; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREVALENCE; SYSTOLE; TTR GENE; AMYLOIDOSIS; BLOOD; COHORT ANALYSIS; ETHNOLOGY; FOLLOW UP; GENETICS; HEART FAILURE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; RESTRICTIVE CARDIOMYOPATHY;

AFRICAN AMERICANS; AGED; AMYLOIDOSIS; CARDIOMYOPATHY, RESTRICTIVE; COHORT STUDIES; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEART FAILURE; HETEROZYGOTE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREALBUMIN;

EID: 84920396906     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1404852     Document Type: Article

References (23)

1. Falk RH, Dubrey SW. Amyloid heart disease. Prog Cardiovasc Dis 2010;52:347-61.
2. Erratum, Prog Cardiovasc Dis 2010; 52: 445-7.
3. Ando Y, Nakamura M, Araki S. Trans-thyretin-related familial amyloidotic poly-neuropathy. Arch Neurol 2005;62:1057-62.
4. Jacobson DR, Pastore RD, Yaghoubian R, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac am-yloidosis in black Americans. N Engl J Med 1997;336:466-73.
5. Rapezzi C, Quarta CC, Obici L, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amy-loidosis with exclusively cardiac pheno-type: an Italian perspective. Eur Heart J 2013;34:520-8.
6. Rowczenio D, Wechalekar A. Mutations in hereditary amyloidosis (http://www.amyloidosismutations.com/mut-attr.php).
7. Jiang X, Buxbaum JN, Kelly J W. The V122I cardiomyopathy variant of trans-thyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis. Proc Natl Acad Sci USA 2001;98:14943-8.
8. Jacobson DR, Gorevic PD, Buxbaum JN. A homozygous transthyretin variant associated with senile systemic amyloido-sis: evidence for a late-onset disease of genetic etiology. Am J Hum Genet 1990; 47:127-36.
9. Buxbaum J, Alexander A, Koziol J, Ta-goe C, Fox E, Kitzman D. Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies. Am Heart J 2010;159:864-70.
10. Jacobson D, Tagoe C, Schwartzbard A, Shah A, Koziol J, Buxbaum J. Relation of clinical, echocardiographic and elec-trocardiographic features of cardiac amy-loidosis to the presence of the transthyre-tin V122I allele in older African-American men. Am J Cardiol 2011;108:440-4.
11. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol 1989;129:687-702.
12. Grove ML, Yu B, Cochran BJ, et al. Best practices and joint calling of the Hu-manExome BeadChip: the CHARGE Consortium. PLoS One 2013;8(7):e68095.
13. Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). Am J Cardiol 2008;101:1016-22.
14. Rosamond WD, Chang PP, Baggett C, et al. Classification of heart failure in the Atherosclerosis Risk in Communities (ARIC) study: a comparison of diagnostic criteria. Circ Heart Fail 2012;5:152-9.
15. Shah AM, Cheng S, Skali H, et al. Rationale and design of a multicenter echocardiographic study to assess the relationship between cardiac structure and function and heart failure risk in a bira-cial cohort of community-dwelling elderly persons: the Atherosclerosis Risk in Communities study. Circ Cardiovasc Imaging 2014;7:173-81.
16. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-63.
17. Cheng S, Larson MG, McCabe EL, et al. Reproducibility of speckle-tracking-based strain measures of left ventricular function in a community-based study. J Am Soc Echocardiogr 2013;26:1258-66.
18. Yingchoncharoen T, Agarwal S, Popovic ZB, Marwick TH. Normal ranges of left ventricular strain: a meta-analysis. J Am Soc Echocardiogr 2013;26:185-91.
19. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J He-matol 2005;79:319-28.
20. Folsom AR, Yamagishi K, Hozawa A, Chambless LE. Absolute and attributable risks of heart failure incidence in relation to optimal risk factors. Circ Heart Fail 2009;2:11-7.
21. Kottgen A, Russell SD, Loehr LR, et al. Reduced kidney function as a risk factor for incident heart failure: the Atherosclerosis Risk in Communities (ARIC) study. J Am Soc Nephrol 2007;18:1307-15.
22. Coelho T, Maurer MS, Suhr OB. THAOS-The Transthyretin Amyloido-sis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin 2013;29: 63-76.
23. Bhuiyan T, Helmke S, Patel AR, et al. Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amy-loidosis secondary to V122I mutations and wild-type transthyretin: Transthyre-tin Cardiac Amyloid Study (TRACS). Circ Heart Fail 2011;4:121-8.